Aarti Drugs Limited has announced the incorporation of a new step-down subsidiary in Chile, expanding its international pharmaceutical operations through its existing subsidiary structure. The company disclosed this development under Regulation 30 of the SEBI Listing Regulations on March 2, 2026.

New Subsidiary Formation

The newly incorporated entity, Tripharma Chile SpA, was established on February 27, 2026, through Pinnacle Chile SpA, which is already a subsidiary of Aarti Drugs Limited. The certificate of registration was processed by the Registry of Companies and Societies, Government of Chile, on February 27, 2026, with company officials being notified on March 2, 2026.

Business Operations and Objectives

Tripharma Chile SpA will operate in the pharmaceutical industry, focusing on marketing formulation drugs and participating in both tender and private markets in Chile. The company's business model aligns with the operations of its holding companies, maintaining consistency within the Aarti Drugs group's pharmaceutical focus.

Corporate Structure

The incorporation creates a multi-tiered subsidiary structure where Tripharma Chile SpA becomes a step-down subsidiary of Aarti Drugs Limited. Pinnacle Chile SpA, which is a direct subsidiary of Aarti Drugs Limited, holds 100% shareholding in the newly formed Tripharma Chile SpA. This structure allows Aarti Drugs to maintain operational control while establishing a local presence in the Chilean pharmaceutical market.

Financial and Regulatory Details

The incorporation involved a cash consideration of Chilean Peso 10,00,000 as share capital contribution, distributed across 10,00,000 shares. The company confirmed that no specific governmental or regulatory approvals were required for this incorporation, streamlining the establishment process in Chile.

This strategic move represents Aarti Drugs Limited's continued expansion in international markets, particularly in South America, through its pharmaceutical operations and subsidiary network.

Aarti Drugs Limited has announced an interim dividend of ₹2 per share for its shareholders, with the board of directors declaring the dividend at their meeting held on February 3, 2026. The company has set February 9, 2026 as the record date for determining eligible shareholders.

Dividend Declaration Details

The pharmaceutical company's board approved the interim dividend payment of ₹2 per equity share of ₹10 each, representing a 20% dividend for the financial year 2025-26. This dividend distribution demonstrates the company's commitment to returning value to its investor base.

Record Date and Compliance

As per Regulation 42(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Monday, February 9, 2026 has been fixed as the record date for the interim dividend payment. Shareholders holding shares on this date will be eligible to receive the dividend.

The company has informed both BSE Limited and National Stock Exchange of India Limited about this dividend declaration, maintaining compliance with regulatory requirements under Regulation 42(1)(a) and Regulation 43 of SEBI LODR Regulations, 2015.

Shareholder Benefits

The interim dividend announcement provides immediate returns to shareholders without waiting for the annual dividend declaration. This approach allows Aarti Drugs Limited to distribute profits as they are generated, providing regular income streams to investors and reflecting the company's financial stability and cash flow generation capabilities.